Tibet Weixinkang Medicine Co., Ltd. (SHA:603676)

China flag China · Delayed Price · Currency is CNY
11.04
+0.24 (2.22%)
At close: Mar 10, 2026
15.36%
Market Cap 4.77B
Revenue (ttm) 1.17B
Net Income (ttm) 222.08M
Shares Out 432.33M
EPS (ttm) 0.52
PE Ratio 21.30
Forward PE n/a
Dividend 0.33 (3.03%)
Ex-Dividend Date Nov 26, 2025
Volume 1,255,400
Average Volume 1,821,365
Open 10.95
Previous Close 10.80
Day's Range 10.85 - 11.04
52-Week Range 7.90 - 14.94
Beta -0.03
RSI 49.62
Earnings Date Apr 24, 2026

About Tibet Weixinkang Medicine

Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. The company offers parenteral nutrition vitamins; electrolyte supplements; intravenous iron, trace, electrolytes, and amino acids supplements; antibiotics; acetylcysteine solution for inhalation; medicine for liver diseases; and other special fields. It also offers injection multivitamins, potassium magnesium aspartate for injection, iron sucrose injection, potassium aspartate injection, etc. The com... [Read more]

Sector Healthcare
Founded 2002
Employees 689
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 603676
Full Company Profile

Financial Performance

In 2024, Tibet Weixinkang Medicine's revenue was 1.30 billion, a decrease of -1.69% compared to the previous year's 1.32 billion. Earnings were 246.17 million, an increase of 15.02%.

Financial Statements

News

There is no news available yet.